Phase II study in idiopathic pulmonary fibrosis completes enrolment
Drug Discovery World
JUNE 24, 2024
Insilico Medicine has completed patient enrolment in a Phase IIa study in China, which is investigating the safety, tolerability, and preliminary efficacy of AI-designed TNIK inhibitor INS018_055 for idiopathic pulmonary fibrosis (IPF). The randomised, double-blind, placebo-controlled study is being conducted across 29 clinical centres in China and has completed enrolment of the planned target of 71 patients in four participant groups, including three experimental and one placebo.
Let's personalize your content